Mission and vision
Our mission is to develop new biotherapeutic entities against specific targets derived from our integrated genomics-based therapeutic target discovery platform. Initially, Alethia is focusing its resources in the field of epithelial ovarian cancer and severe bone loss and intends to gradually migrate to other therapeutic fields over the years.
Our strategy is to maintain a very effective target to pre-clinical discovery group and build a strong intellectual property position around our proprietary therapeutic targets. Consequently, a rich pipeline of drug candidates is developed to leverage some of the proprietary targets discovered internally in selected niche therapeutic fields.
In the short-term, Alethia’s goal is to pursue the successful integration of its therapeutic lead optimization and clinical development capability with its core target identification and validation discovery platform.
